Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Sumitomo takes out Urovant, and Myovant beckons
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
Sumitomo bets on Roivant to solve its patent expiry woes
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Short the launch starts early for Urovant
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
First big test approaches for Urovant
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
